Matches in SemOpenAlex for { <https://semopenalex.org/work/W2285459301> ?p ?o ?g. }
- W2285459301 endingPage "89.e10" @default.
- W2285459301 startingPage "89.e1" @default.
- W2285459301 abstract "BackgroundAlterations in circulating angiogenic factors are associated with the diagnosis of preeclampsia and correlate with adverse perinatal outcomes during the third trimester.ObjectiveAnalysis of the sequential levels of plasma angiogenic factors among patients admitted for evaluation of preeclampsia.Study DesignWe performed an observational study among women with singleton pregnancies admitted to Beth Israel Deaconess Medical Center, Boston, Massachusetts, for evaluation of preeclampsia at less than 37 weeks of gestation. Plasma samples were collected on admission and daily for the first 3 days and then weekly until delivery. Doppler ultrasound was performed on admission (within 48 hours) and then weekly (within 24 hours of blood collection) to evaluate uteroplacental and umbilical blood flows. Maternal demographics, hospital course, mode of delivery, diagnosis of hypertensive disorder, adverse maternal outcomes (elevated liver function enzymes, low platelet count, pulmonary edema, cerebral hemorrhage, convulsion, acute renal insufficiency, or maternal death), and adverse fetal/neonatal outcomes (small for gestational age, abnormal umbilical artery Doppler, fetal death, and neonatal death) were recorded. Circulating angiogenic factors (soluble fms-like tyrosine kinase and placental growth factor were measured on automated platform in a single batch after delivery and in a blinded fashion. Data are presented as median (25th to 75th centile), mean, or proportions as appropriate.ResultsDuring the study period, data from 100 women were analyzed for the study, and 43 had adverse outcomes. Women with adverse outcomes had lower gestational age of delivery, higher systolic and diastolic blood pressures during hospitalization, and lower birthweight and placental weight (all P < .01). These patients had higher soluble fms-like tyrosine kinase and soluble fms-like tyrosine kinase/placental growth factor ratio on admission and continued to have an increase in levels throughout hospital course. The median (25th to 75th) soluble fms-like tyrosine kinase/placental growth factor ratio among patients with adverse outcomes was 205.9 (72.5, 453.1) versus 47.5 (9.7, 87.0) among women without adverse outcomes (P < .001). The median (25th to 75th) absolute change per day in soluble fms-like tyrosine kinase levels (pg/mL) was 491.0 pg/mL (120.3, 1587.2) among women with adverse outcomes versus 81.3 pg/mL (−177.9, 449.0) among women without adverse outcomes (P = .01). Similarly the absolute change per day for soluble fms-like tyrosine kinase/placental growth factor ratio was 15.1 (1.8, 58.1) versus 2.7 (−0.6, 8.3) between the two groups (P = .004). The mean (range) days from admission to delivery was 6 (0–35) among subjects with soluble fms-like tyrosine kinase/placental growth factor ratio ≥85 and 14 (0–39) below a ratio of 85 (P < .001). The positive predictive value for plasma soluble fms-like tyrosine kinase/placental growth factor ratio ≥85 at admission for indicated delivery within 2 weeks was 91% (83–99%). Admission plasma soluble fms-like tyrosine kinase/placental growth factor ratio positively correlated with pre-delivery uterine artery resistive index (r = 0.35; P = .004).ConclusionAmong women admitted for evaluation of preeclampsia, women at risk for adverse pregnancy outcomes have higher soluble fms-like tyrosine kinase/placental growth factor ratio on admission, which continued to rise until delivery. Women with high soluble fms-like tyrosine kinase/placental growth factor ratios delivered sooner than women with low soluble fms-like tyrosine kinase/placental growth factor levels. These data support the hypothesis that targeting angiogenic imbalance in preeclampsia may lead to prolongation of pregnancy. Alterations in circulating angiogenic factors are associated with the diagnosis of preeclampsia and correlate with adverse perinatal outcomes during the third trimester. Analysis of the sequential levels of plasma angiogenic factors among patients admitted for evaluation of preeclampsia. We performed an observational study among women with singleton pregnancies admitted to Beth Israel Deaconess Medical Center, Boston, Massachusetts, for evaluation of preeclampsia at less than 37 weeks of gestation. Plasma samples were collected on admission and daily for the first 3 days and then weekly until delivery. Doppler ultrasound was performed on admission (within 48 hours) and then weekly (within 24 hours of blood collection) to evaluate uteroplacental and umbilical blood flows. Maternal demographics, hospital course, mode of delivery, diagnosis of hypertensive disorder, adverse maternal outcomes (elevated liver function enzymes, low platelet count, pulmonary edema, cerebral hemorrhage, convulsion, acute renal insufficiency, or maternal death), and adverse fetal/neonatal outcomes (small for gestational age, abnormal umbilical artery Doppler, fetal death, and neonatal death) were recorded. Circulating angiogenic factors (soluble fms-like tyrosine kinase and placental growth factor were measured on automated platform in a single batch after delivery and in a blinded fashion. Data are presented as median (25th to 75th centile), mean, or proportions as appropriate. During the study period, data from 100 women were analyzed for the study, and 43 had adverse outcomes. Women with adverse outcomes had lower gestational age of delivery, higher systolic and diastolic blood pressures during hospitalization, and lower birthweight and placental weight (all P < .01). These patients had higher soluble fms-like tyrosine kinase and soluble fms-like tyrosine kinase/placental growth factor ratio on admission and continued to have an increase in levels throughout hospital course. The median (25th to 75th) soluble fms-like tyrosine kinase/placental growth factor ratio among patients with adverse outcomes was 205.9 (72.5, 453.1) versus 47.5 (9.7, 87.0) among women without adverse outcomes (P < .001). The median (25th to 75th) absolute change per day in soluble fms-like tyrosine kinase levels (pg/mL) was 491.0 pg/mL (120.3, 1587.2) among women with adverse outcomes versus 81.3 pg/mL (−177.9, 449.0) among women without adverse outcomes (P = .01). Similarly the absolute change per day for soluble fms-like tyrosine kinase/placental growth factor ratio was 15.1 (1.8, 58.1) versus 2.7 (−0.6, 8.3) between the two groups (P = .004). The mean (range) days from admission to delivery was 6 (0–35) among subjects with soluble fms-like tyrosine kinase/placental growth factor ratio ≥85 and 14 (0–39) below a ratio of 85 (P < .001). The positive predictive value for plasma soluble fms-like tyrosine kinase/placental growth factor ratio ≥85 at admission for indicated delivery within 2 weeks was 91% (83–99%). Admission plasma soluble fms-like tyrosine kinase/placental growth factor ratio positively correlated with pre-delivery uterine artery resistive index (r = 0.35; P = .004). Among women admitted for evaluation of preeclampsia, women at risk for adverse pregnancy outcomes have higher soluble fms-like tyrosine kinase/placental growth factor ratio on admission, which continued to rise until delivery. Women with high soluble fms-like tyrosine kinase/placental growth factor ratios delivered sooner than women with low soluble fms-like tyrosine kinase/placental growth factor levels. These data support the hypothesis that targeting angiogenic imbalance in preeclampsia may lead to prolongation of pregnancy." @default.
- W2285459301 created "2016-06-24" @default.
- W2285459301 creator A5004624991 @default.
- W2285459301 creator A5009663524 @default.
- W2285459301 creator A5018851209 @default.
- W2285459301 creator A5028559337 @default.
- W2285459301 creator A5030159705 @default.
- W2285459301 creator A5030601893 @default.
- W2285459301 creator A5047323588 @default.
- W2285459301 creator A5055915308 @default.
- W2285459301 creator A5087669596 @default.
- W2285459301 date "2016-07-01" @default.
- W2285459301 modified "2023-09-30" @default.
- W2285459301 title "Sequential plasma angiogenic factors levels in women with suspected preeclampsia" @default.
- W2285459301 cites W2006245385 @default.
- W2285459301 cites W2010712475 @default.
- W2285459301 cites W2017904618 @default.
- W2285459301 cites W2021964897 @default.
- W2285459301 cites W2058315204 @default.
- W2285459301 cites W2061506872 @default.
- W2285459301 cites W2065594976 @default.
- W2285459301 cites W2074133251 @default.
- W2285459301 cites W2074978990 @default.
- W2285459301 cites W2086073438 @default.
- W2285459301 cites W2091860804 @default.
- W2285459301 cites W2094395765 @default.
- W2285459301 cites W2104310850 @default.
- W2285459301 cites W2113606273 @default.
- W2285459301 cites W2134502189 @default.
- W2285459301 cites W2136047500 @default.
- W2285459301 cites W2154667517 @default.
- W2285459301 cites W2168559361 @default.
- W2285459301 cites W2185931826 @default.
- W2285459301 cites W2233974801 @default.
- W2285459301 cites W71058652 @default.
- W2285459301 doi "https://doi.org/10.1016/j.ajog.2016.01.168" @default.
- W2285459301 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26827880" @default.
- W2285459301 hasPublicationYear "2016" @default.
- W2285459301 type Work @default.
- W2285459301 sameAs 2285459301 @default.
- W2285459301 citedByCount "53" @default.
- W2285459301 countsByYear W22854593012016 @default.
- W2285459301 countsByYear W22854593012017 @default.
- W2285459301 countsByYear W22854593012018 @default.
- W2285459301 countsByYear W22854593012019 @default.
- W2285459301 countsByYear W22854593012020 @default.
- W2285459301 countsByYear W22854593012021 @default.
- W2285459301 countsByYear W22854593012022 @default.
- W2285459301 countsByYear W22854593012023 @default.
- W2285459301 crossrefType "journal-article" @default.
- W2285459301 hasAuthorship W2285459301A5004624991 @default.
- W2285459301 hasAuthorship W2285459301A5009663524 @default.
- W2285459301 hasAuthorship W2285459301A5018851209 @default.
- W2285459301 hasAuthorship W2285459301A5028559337 @default.
- W2285459301 hasAuthorship W2285459301A5030159705 @default.
- W2285459301 hasAuthorship W2285459301A5030601893 @default.
- W2285459301 hasAuthorship W2285459301A5047323588 @default.
- W2285459301 hasAuthorship W2285459301A5055915308 @default.
- W2285459301 hasAuthorship W2285459301A5087669596 @default.
- W2285459301 hasBestOaLocation W22854593011 @default.
- W2285459301 hasConcept C126322002 @default.
- W2285459301 hasConcept C131872663 @default.
- W2285459301 hasConcept C167734588 @default.
- W2285459301 hasConcept C2776871010 @default.
- W2285459301 hasConcept C2777025900 @default.
- W2285459301 hasConcept C2777218350 @default.
- W2285459301 hasConcept C2779234561 @default.
- W2285459301 hasConcept C29456083 @default.
- W2285459301 hasConcept C3017575891 @default.
- W2285459301 hasConcept C54355233 @default.
- W2285459301 hasConcept C71924100 @default.
- W2285459301 hasConcept C86803240 @default.
- W2285459301 hasConceptScore W2285459301C126322002 @default.
- W2285459301 hasConceptScore W2285459301C131872663 @default.
- W2285459301 hasConceptScore W2285459301C167734588 @default.
- W2285459301 hasConceptScore W2285459301C2776871010 @default.
- W2285459301 hasConceptScore W2285459301C2777025900 @default.
- W2285459301 hasConceptScore W2285459301C2777218350 @default.
- W2285459301 hasConceptScore W2285459301C2779234561 @default.
- W2285459301 hasConceptScore W2285459301C29456083 @default.
- W2285459301 hasConceptScore W2285459301C3017575891 @default.
- W2285459301 hasConceptScore W2285459301C54355233 @default.
- W2285459301 hasConceptScore W2285459301C71924100 @default.
- W2285459301 hasConceptScore W2285459301C86803240 @default.
- W2285459301 hasIssue "1" @default.
- W2285459301 hasLocation W22854593011 @default.
- W2285459301 hasLocation W22854593012 @default.
- W2285459301 hasOpenAccess W2285459301 @default.
- W2285459301 hasPrimaryLocation W22854593011 @default.
- W2285459301 hasRelatedWork W1980283574 @default.
- W2285459301 hasRelatedWork W2037748478 @default.
- W2285459301 hasRelatedWork W2066664544 @default.
- W2285459301 hasRelatedWork W2124382171 @default.
- W2285459301 hasRelatedWork W2606562919 @default.
- W2285459301 hasRelatedWork W2615392318 @default.
- W2285459301 hasRelatedWork W2902115400 @default.
- W2285459301 hasRelatedWork W3015469752 @default.
- W2285459301 hasRelatedWork W3160091635 @default.